The Regulator of G-protein Signaling 8 (RGS8) is a member of the RGS protein family, which plays a critical role in modulating G-protein-coupled receptor (GPCR) signaling. RGS8 acts as a GTPase-activating protein (GAP) for Gαi/o and Gαq subunits, accelerating GTP hydrolysis to terminate downstream signaling. It is predominantly expressed in the central nervous system, particularly in regions like the cerebellum, hippocampus, and cerebral cortex, suggesting roles in neuronal development, synaptic plasticity, and motor coordination. Dysregulation of RGS8 has been implicated in neurological disorders, including Parkinson’s disease and mood disorders, as well as certain cancers.
RGS8 antibodies are essential tools for detecting and quantifying RGS8 protein expression, localization, and functional interactions in research. They are widely used in techniques such as Western blotting, immunohistochemistry (IHC), immunofluorescence (IF), and co-immunoprecipitation (Co-IP) to study RGS8’s regulatory mechanisms in cellular and disease models. Commercial RGS8 antibodies are typically raised against specific epitopes, often within the conserved RGS domain or variable N-/C-terminal regions, and validated for species cross-reactivity (e.g., human, mouse, rat).
These antibodies contribute to elucidating RGS8’s physiological roles, such as its involvement in neurotransmitter signaling, and its potential as a therapeutic target. Researchers also utilize RGS8 antibodies to explore its interactions with GPCRs, G-proteins, and other signaling molecules, providing insights into pathways relevant to neurodegeneration, cancer progression, and psychiatric conditions.